The February issue of The Oncology Nurse-APN/PA (TON) is filled with important news and insights for today’s oncology nurse.
St. Luke’s Cancer Institute, Boise, ID, is celebrating its 50th anniversary this year. Formerly known as Mountain States Tumor Institute, St. Luke’s employs medical and radiation oncology specialists, as well as fellowship-trained cancer surgeons in areas such as thoracic, hepatobiliary, gynecologic, and urologic oncology. The facility also offers autologous and allogeneic bone marrow and stem-cell transplantation and is a National Marrow Donor Program Apheresis Center. In addition, St. Luke’s is home to Idaho’s only pediatric cancer program and federally sponsored hemophilia center.
San Francisco, CA—An increasing number of biosimilars have been approved in the United States, but many clinicians are still poorly informed about what constitutes a biosimilar, and what is involved in their unique pathway to approval, said Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City. He discussed this topic at the NCCN 2019 Hematologic Malignancies meeting.
San Francisco, CA—There is no shortage of research on psychosocial issues in patients with cancer, but implementation of this evidence in clinical practice has a long way to go, according to data presented at the 2019 Supportive Care in Oncology Symposium.
Orlando, FL—Today’s patient with cancer is concerned with more than just cell counts. These patients want to discuss topics such as parenting, financial toxicity, and sex and intimacy, according to Laura Holmes Haddad, author of This Is Cancer, and a cancer survivor.
Leukemia is the most frequently diagnosed cancer in children and adolescents, representing approximately 1 of 3 cancers in these populations of patients. Of the 4 main types of leukemia (acute myeloid leukemia, acute lymphocytic leukemia [ALL], chronic myeloid leukemia, and chronic lymphocytic leukemia), ALL is the most common type found in children and adolescents. The following provides key statistics and other helpful information regarding ALL.
San Francisco, CA—Cannabis has been credited as a medicinal plant with benefits ranging from pain and inflammation relief to epileptic seizure reduction to insomnia and anxiety cures, but the evidence is still limited, particularly in the setting of advanced cancer.
Barcelona, Spain—Results of the new clinical trial RADICALS-RT indicate that using salvage radiotherapy immediately after surgery leads to equivalent outcomes in terms of progression-free survival (PFS) versus adjuvant radiotherapy in men with prostate cancer undergoing radical prostatectomy. These late-breaking results were presented at the ESMO Congress 2019 by lead investigator Chris Parker, MD, FRCR, MRCP, Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, England.
Barcelona, Spain—Alterations in the fibroblast growth factor receptor (FGFR)2 gene have been identified as driver mutations in cholangiocarcinoma (CCA). Durable objective responses were observed in >33% of patients with locally advanced or metastatic CCA and FGFR2 rearrangements or fusions who received treatment with pemigatinib, a selective oral inhibitor of FGFR1, FGFR2, and FGFR3. Data from the single-arm, open-label phase 2 clinical trial FIGHT-202, which was presented at the ESMO Congress 2019, revealed that investigational pemigatinib induced a response in 35.5% of the 107 patients with FGFR2 fusions or rearrangements (cohort A), with a median duration of response of 7.5 months.
To sign up for our newsletter or print publications, please enter your contact information below.
Subscribe to recieve the free, monthly TON print publication and TON weekly e‑newsletter.